TCM
ESPR

Tang Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Tang Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,850,000
Closed -$5.53M – 113
2023
Q4 		$5.53M Hold
1,850,000
– – 0.51% 49
2023
Q3 		$1.81M Hold
1,850,000
– – 0.26% 74
2023
Q2 		$2.57M Hold
1,850,000
– – 0.38% 63
2023
Q1 		$2.94M Buy
+1,850,000
New +$9.55M 0.44% 56
2022
Q4 		– Sell
-500,000
Closed -$3.35M – 97
2022
Q3 		$3.35M Buy
+500,000
New +$3.43M 0.41% 54

Other funds holding ESPR

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $408M AUM 318.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $2.17B AUM 169.27% 1-Year Est. Return